Abstract:Objective: Although the mechanisms behind pharmacokinetic (PK) drug-drug interactions (DDIs) are well-documented, bridging the gap between this knowledge and clinical evidence of DDIs, especially for serious adverse drug reactions (SADRs), remains challenging. While leveraging the FDA Adverse Event Reporting System (FAERS) database along with disproportionality analysis tends to detect a vast number of DDI signals, this abundance complicates further investigation, such as validation through clinical trials. Our study proposed a framework to efficiently prioritize these signals and assessed their reliability using multi-source Electronic Health Records (EHR) to identify top candidates for further investigation. Methods: We analyzed FAERS data spanning from January 2004 to March 2023, employing four established disproportionality methods: Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagating Neural Network (BCPNN). Building upon these models, we developed four ranking models to prioritize DDI-SADR signals and cross-referenced signals with DrugBank. To validate the top-ranked signals, we employed longitudinal EHRs from Vanderbilt University Medical Center and the All of Us research program. The performance of each model was assessed by counting how many of the top-ranked signals were confirmed by EHRs and calculating the average ranking of these confirmed signals. Results: Out of 189 DDI-SADR signals identified by all four disproportionality methods, only two were documented in the DrugBank database. By prioritizing the top 20 signals as determined by each of the four disproportionality methods and our four ranking models, 58 unique DDI-SADR signals were selected for EHR validations. Of these, five signals were confirmed. The ranking model, which integrated the MGPS and BCPNN, demonstrated superior performance by assigning the highest priority to those five EHR-confirmed signals. Conclusion: The fusion of disproportionality analysis with ranking models, validated through multi-source EHRs, presents a groundbreaking approach to pharmacovigilance. Our study's confirmation of five significant DDI-SADRs, previously unrecorded in the DrugBank database, highlights the essential role of advanced data analysis techniques in identifying ADRs.

Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system

Study of Serious Adverse Drug Reactions Using FDA-approved Drug Labeling and MedDRA

Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis

Application of Data Mining Algorithm to Detect Adverse Drug Reaction Signal

Application of Association Rules Analysis in Mining Adverse Drug Reaction Signals

Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study

Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database

Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data

Safety Analysis of Therapeutic Drugs for Breast Cancer Patients and Construction of a Predictive Model for Serious Adverse Drug Reactions

Establishment of a Rapid Identification of Adverse Drug Reaction Program in R Language Implementation Based on Monitoring Data

Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records

Data Mining and Analytical Models to Predict and Identify Adverse Drug-drug Interactions

Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning

Data Mining and Safety Analysis of Avatrombopag: a Retrospective Pharmacovigilance Study Based on the US Food and Drug Administration’s Adverse Event Reporting System

Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

A Survey on Computational Approaches to Predicting Adverse Drug Reactions.

Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data

A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system